The ARCTIC Trial: Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19

Acute Respiratory Distress Clinical Trial

Official title:
Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19 (The ARCTIC Trial)

Status Withdrawn

Clinical Trial Summary

This is a phase II study to test adenosine efficacy for down-regulation of the overwhelming inflammation of COVID-19 in the lungs as reflected by clinical recovery of lung function; resolution of clinically relevant markers of lung function, and resolution of systemic markers of inflammation and coagulation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04588441
Study type	Interventional
Source	University of Florida
Contact
Status	Withdrawn
Phase	Phase 2
Start date	December 2023
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03033251` - High Flow Nasal Cannula Versus Non-Invasive Ventilation in Exacerbations of Chronic Obstructive Pulmonary Disease	N/A
Completed	`NCT01710891` - Laryngoscope Versus CMAC for Endotracheal Intubation in Patients Undergoing Emergent Airway Management	Phase 4
Completed	`NCT02766946` - Diaphragmatic Atrophy Related to Mechanical Ventilation	N/A
Completed	`NCT03780933` - the Effect of High Dose Ascorbic Acid on Critically Ill Patients With ARDS	N/A
Completed	`NCT01928238` - Physiologic Effects of Noninvasive Neurally Adjusted Ventilatory Assist (NAVA) Versus Noninvasive Pressure Support Ventilation in Patients at Risk for Respiratory Distress Needed Preventive Used of Noninvasive Ventilation After Extubation.	N/A